This issue is focused around immuno-oncology and we have upcoming issues on drug-repurposing, anti-microbial resistance and computer-aided drug design. "
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Expanding the reach of our articles
We are particularly proud of our partnership with RxNet [6] , a free online resource that covers all aspects of pharma R&D. Members of the site gain access to exclusive additional content that builds upon our open access articles, such as our peek behind the paper interview with author J Bajorath. In this interview, he gave further insight into his paper on a novel computational methodology to evaluate chemical optimization [7] . Working with the RxNet Editorial team, we were delighted to release the first edition of our Glossary of Drug Discovery last August [8] . Thanks to the help of our expert panel, we compiled a list of all the key terms used in drug discovery -from abbreviated new drug application to Z' factor -and provided handy definitions for your reference. The full glossary is available online and we also hand out physical copies of the book at relevant conferences, so watch out for our booths.
In addition, we continue to utilize the power of social media and share all new work on Twitter in order to insure it reaches the largest audience possible; if you do not already, we welcome you to follow us on Twitter (@fsdrugdiscovery).
Conferences in 2020
Throughout 2019, we were lucky enough to attend multiple exciting conferences, including AAPS PharmSci 360 (TX, USA, 3-6 November 2019), ELRIG Drug Discovery (Liverpool, UK, 5-6 November 2019) and the 4th Medicinal Chemistry and Protein Degradation Summit (London, UK, 28-29 October 2019). It is always great to be able to meet our readers and authors and hear feedback on the journal.
If you have any suggestions for conferences in 2020 you would like to meet us at, please let us know. We will be attending various meetings in 2020 with members of the RxNet team, so be sure to look out for our booth and grab a copy of our glossary if you get the chance.
Our Editorial Board & contributors
We are hugely thankful to our Editorial Board [9] for their help in creating Future Drug Discovery and their contributions thus far. Our board comprises experts from across the globe crossing both academia and industry and will be joined in 2020 by a panel of early career researchers who will work to help us ensure the journal is supporting researchers at all career levels. If you would be interested in joining our Early Career Panel, please get in touch; we would be delighted to hear your input. We would also like to thank all the authors and peer reviewers for their contributions in 2019, without whom Volume 1 would not have been possible -we look forward to working with them again in 2020.
Conclusion
Following a successful launch, we are excited to see the journal grow and gain recognition in the field over the coming years. Our plans for themed issues and a focus on early career research mean we have plenty to keep us busy in 2020, although we value any input you may have. If you have any ideas for the journal, be it an outline for an article or a theme for an issue, we would love to hear it, so please get in touch.
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